In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dynogen Pharmaceuticals, Inc.

Latest From Dynogen Pharmaceuticals, Inc.

Astellas calls time on ex-Dynogen US facility as it tidies R&D network

Astellas is to close down a small research subsidiary in the US by the end of this year, as it looks to control costs and rationalise its corporate R&D effort.

Gynecology & Urology Japan

Biotechs Target the GI Tract

Regulatory risk and a mature market for some indications have driven Big Pharma players from the gastrointestinal space. That signals possible biotech opportunity. In this issue, we profile Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences.


2010 Scrip 100 - Survivors of the shakeout

Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan.

Metabolic Disorders Cancer

Alnara Pharmaceuticals makes appointment

Alnara Pharmaceuticals, a US company developing non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, has appointed Dr Lee Brettman to the newly created position of chief medical officer. He has almost 20 years' pharmaceutical industry leadership experience; before joining Alnara, Dr Brettman was the founder, president and CEO of Dynogen Pharmaceuticals. He has also worked at Oxford Bioscience Partners and Millennium Pharmaceuticals.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals